The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 2008; 165:490-496
(published online February 15, 2008; doi: 10.1176/appi.ajp.2007.07071110)
© 2008 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Rais, M.
* Articles by Kahn, R.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Rais, M.
* Articles by Kahn, R.
Related Collections
* Schizophrenia Spectrum Disorders
* Cannabis
* Other Neuroanatomy
*Related Article

Excessive Brain Volume Loss Over Time in Cannabis-Using First-Episode Schizophrenia Patients

Monica Rais, M.D., Wiepke Cahn, M.D., Ph.D., Neeltje Van Haren, Ph.D., Hugo Schnack, Ph.D., Esther Caspers, M.S., Hilleke Hulshoff Pol, Ph.D., and René Kahn, M.D., Ph.D.

OBJECTIVE: Cerebral gray matter volume reductions have been found to progress over time in schizophrenia, with larger decreases related to poorer outcome, which has also been associated with cannabis use in schizophrenia patients. Progressive gray matter changes in patients who use cannabis may be more extensive than in those who do not. METHOD: Patients with recent-onset schizophrenia (N=51) and matched healthy subjects (N=31) were included. For all subjects, magnetic resonance imaging scans were obtained at inclusion (T0) and at 5-year follow-up (T5). Nineteen patients used cannabis but no other illicit drugs; 32 patients did not use any drugs during the 5-year follow-up. At T5, clinical outcome was measured. Cumulative amount of antipsychotic medication during the interval was calculated. At T0 and T5, total brain, gray and white matter, and lateral and third ventricle volumes were measured. Univariate analysis of covariance and pairwise comparisons were performed. Result: Schizophrenia patients showed a larger gray matter volume decrease over time than healthy subjects. They also showed larger increases in lateral and third ventricle volumes than healthy subjects and patients who did not use cannabis during follow-up. This decrement was significantly more pronounced in the patients who continued to use cannabis. These differences could not be attributed to outcome or baseline characteristics. CONCLUSIONS: First-episode schizophrenia patients who use cannabis show a more pronounced brain volume reduction over a 5-year follow-up than patients with schizophrenia who do not use cannabis. These results may help explain some of the detrimental effects of cannabis use in schizophrenia.


Related Article:

In This Issue
Am J Psychiatry 2008 165: A50. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Am. J. PsychiatryHome page
D. F. ZULLINO, L. WABER, and Y. KHAZAAL
Cannabis and the Course of Schizophrenia
Am J Psychiatry, October 1, 2008; 165(10): 1357 - 1358.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org